Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 801–900 of 1,000
Ding, Q., Yue, J., Xue, L.-F., Xu, Y., & Xiao, W. (2022) · European journal of medical research · doi:10.1186/s40001-022-00757-1 · Cited by 3
Mayyas, F., & Gharram, T. A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02318-z · Cited by 3
“The TGF-β, a highly profibrotic mediator, is extensively implicated in the pathogenesis of fibrosis (Frangogiannis 2020).”
BackgroundSulfur-containing amino acids and their metabolites in atrial fibrosis
Wang, R., Qi, Y., Ding, C. H., & Zhang, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1063241 · Cited by 3
“The myofibroblasts showed greater mobile and contractile and produced a large amount of extracellular matrix (Frangogiannis, 2019, 2021).”
BackgroundToyoda, A., Kawakami, K., Amano, Y., Nishizawa, H., Nakamura, S.-I., Kawase, T., Yoshida, Y., Suzuki, H., & Tsukahara, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021237 · Cited by 3
Hydroxysafflor yellow A mitigates myocardial fibrosis induced by isoproterenol and angiotensin II.
Cong, P., Huang, G., Zhao, Y., & Lan, Y. (2022) · PubMed · Cited by 3
Miao, S., Wang, L., Guan, S., Gu, T., Wang, H., Shangguan, W., Wang, W., Liu, Y., & Liang, X. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023250 · Cited by 3
Integrins in Cardiac Form, Function, and Disease
Manso, A. M., Romaine, A., Christensen, G., & Ross, R. S. (2023) · Biology of extracellular matrix · doi:10.1007/978-3-031-23781-2_4 · Cited by 3
Endogenously produced hyaluronan contributes to the regulation of peritoneal adhesion development
Kocurková, A., Kerberova, M., Nešporová, K., Lehká, K., Sandanusova, M., Šimek, M., Velebný, V., Kubala, L., & Ambrožová, G. (2023) · BioFactors · doi:10.1002/biof.1957 · Cited by 3
Dallagnol, J. C. C., Volkovich, M., Chatenet, D., Allen, B. G., & Hébert, T. E. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00319 · Cited by 3
Awwad, L., & Aronheim, A. (2023) · Cells · doi:10.3390/cells12182289 · Cited by 3
“Fibrosis, which is typically associated with HF especially following myocardial infarction (MI), is part of wound healing process characterized by injury, inflammation, myofibroblast activation, matrix deposition and remodeling [27].”
BackgroundZhang, C., Yao, L., Liu, M., & Zhou, Y. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2310078 · Cited by 3
“Myocardial interstitial fibrosis can also be promoted by systemic hypertension, aging, obesity, and diabetes [19].”
BackgroundDu, B., Shi, H.-T., Xiao, L., Li, Y., Yao, R., Liang, C., Tian, X., Yang, L.-L., Kong, L., Du, J., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130542 · Cited by 3
Li, X., Shi, S., Li, Z., Wang, Y., Qi, X., Zhang, R., Liu, Z., & Cheng, Y. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1616 · Cited by 3
Liu, D., Zeng, F., Chen, Z., Qin, Z. H., & Liu, Z. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13813 · Cited by 3
Ge, M., Zhang, L., Du, J., Jin, H., Lv, B., & Huang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34260 · Cited by 3
“Excessive proliferation of cardiac fibroblasts is a crucial pathological basis of myocardial fibrosis [1 – 4].”
BackgroundAndrographolide: A promising therapeutic agent against organ fibrosis
Dai, W., Wu, J., Li, K., Xu, Y., Wang, W., & Xiao, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116992 · Cited by 3
Role of STK38L in atrial fibrillation-associated myocardial fibrosis: findings from RNA-seq analysis
Zhang, Y., Zhang, R., Wang, X., Fang, S., & Wang, B. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-164 · Cited by 3
Relaxin Inhibits Angiotensin II-Induced Cardiac Fibrosis by Activating NO/cGMP Signaling Pathway
Liu, J. (2024) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2024.4605 · Cited by 3
Upregulation of the maresin pathway and PGE2 metabolism in the failing human left ventricle
Bouhadoun, A., Manikpurage, H. D., Merheb, G., Boutigny, A., Dubourdeau, M., Baillif, V., Deschildre, C., Para, M., Sannier, A., Deschamps, L., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2025.159645 · Cited by 3
Xu, Z., Shen, Y., Luo, X., Wang, J., Zhou, Q., Han, X., Ren, J., Wang, L., & Liang, G. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70180 · Cited by 3
“…changes is angiotensin II (Ang II), a critical effector agent of the renin – angiotensin system, known to induce cardiomyocyte hypertrophy, fibrosis, and ultimately heart failure through its engagement with various downstream signalling pathways (Forrester et al., 2018; Frangogiannis, 2021).”
Łukawska-Tatarczuk, M. M., Pawlak, A., Zieliński, J., Franek, E., Czupryniak, L., & Mrozikiewicz‐Rakowska, B. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0041 · Cited by 3
p53 at the Intersection of Cardiac Fibroblast Proliferation and Activation: Answers and Questions
Ghigo, A., & Ameri, P. (2023) · Circulation Research · doi:10.1161/circresaha.123.323209 · Cited by 3
Primary myocardial fibrosis — a distinct entity characterized by heterogeneous histology
Pakanen, L., Appel, H., Ahtikoski, A. M., Holm, P. H., Kreus, M., Olsen, K. B., Banner, J., Winkel, B. G., Huikuri, H. V., Kaarteenaho, R. L., et al. (2023) · Cardiovascular Pathology · doi:10.1016/j.carpath.2023.107573 · Cited by 2
Wang, C., Chakraborty, A., Somanader, D. V. N., Nguyen, M., Chen, W., Widdop, R. E., & Samuel, C. S. (2023) · Fibrosis · doi:10.35534/fibrosis.2023.10006 · Cited by 2
Fibroblasts, myofibroblasts and cardiac arrhythmias
Frangogiannis, N. G. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.37 · Cited by 2
Self-citationDai, Q., Zhao, S., Li, W., Liu, K., Tao, X., Li, J., Yao, H., Mu, F., Chen, S., Li, J., et al. (2024) · Rejuvenation Research · doi:10.1089/rej.2023.0068 · Cited by 2
Molecular Pathways for Progression of Myocardial Fibrosis. Potentials of Therapy
Сергеевна, С. А., & Филиппов, Е. В. (2024) · Nauka molodykh (Eruditio Juvenium) · doi:10.23888/hmj2024123478-487 · Cited by 2
Liao, C., Hundscheid, J. H. M., Crawford, J., ten Dijke, P., Coornaert, B., & Danen, E. H. J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101800 · Cited by 4
Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals
Maar, K., Thatcher, J. E., Karpov, E., Rendeki, S., Gallyas, F., & Bock-Marquette, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094131 · Cited by 2
“Conse-quential myocardial fibrosis contributes to pathological remodeling and heart failure [90–92].”
Dauz, J. D., Yazaki, K., Akazawa, Y., Meister, T. A., Kabir, G., Kadowaki, S., Honjo, O., Heximer, S. P., Wald, R. M., Connelly, K. A., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70339 · Cited by 2
MO Oxygen Therapy Prevents Doxorubicin‐Induced Cardiotoxicity
Zhang, L., & Liu, Y. (2025) · Cardiology Research and Practice · doi:10.1155/crp/2729462 · Cited by 2
“In addition, the infltration of infammatory cells forms a vicious cycle with neurohumoral activation, further aggravating the damage and death of cardiomyocytes, leading to myocardial fbrosis, and causing cardiac dysfunction and the occurrence of HF [27–31].”
Yan, H. M., Huang, B. S., Zhang, B., Yun-yao, L., Zhou, Q., Abudoureyimu, A., Cao, G., & Jiang, H. (2025) · Biomedicines · doi:10.3390/biomedicines13061302 · Cited by 2
“Furthermore, we observed that HYBID promotes diffuse fibrosis in the distal myocardium, a phenomenon commonly associated with chronic heart diseases such as aortic stenosis [34], myocardial hypertrophy [35], hypertensive heart disease, and systemic conditions linked to heart failure [36,37].”
Histopathological Analysis of Myocardial Remodeling Following Heart Failure: A Cadaveric Case Report
DeSomma, A., & Lee, J. W. (2025) · Cureus · doi:10.7759/cureus.87889 · Cited by 2
“Additionally, plasma levels of the pro-inflammatory cytokines such as TNF-α , IL-1 β , and IL-6 showed fibrinogenic activities associated with fibrosis formation [11].”
MARCH5 Promotes Cardiac Hypertrophy by Regulating Akt/mTOR/Gsk‐3β/GATA4 Signalling Pathway
Li, G., Wu, F., Fan, L., Zhang, J., & Liao, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70735 · Cited by 2
Karppinen, S., Aho, M., Szabó, Z., Magga, J. M., Vainio, L., Gao, E., Janmey, P. A., Eklund, L., Rasi, K., Miinalainen, I., et al. (2025) · FEBS Journal · doi:10.1111/febs.70212 · Cited by 4
A multiscale mechanobiological model of physiological and pathological cardiac hypertrophy
Xu, S., Chen, X., Peng, X., Li, B., & Feng, X. (2025) · Journal of the Mechanics and Physics of Solids · doi:10.1016/j.jmps.2025.106349 · Cited by 2
Veeram, A., Sistla, R., & Andugulapati, S. B. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115593 · Cited by 2
Vauhkonen, P. K., Kiiskilä, J., Hytönen, S., Koskela, R., Mäyränpää, M. I., & Lindroos, K. M. (2025) · International Journal of Legal Medicine · doi:10.1007/s00414-025-03630-y · Cited by 2
“These findings together sug - gest that among the AAS using population, initially subtle cardiac collagen deposition may progress through perivascular and interstitial fibrosis to replacement scars with no regenerative capacity [21].”
Xu, F., Chen, Y., Xu, M., Li, D., Lu, Y., Zhang, M., Li, J., Li, W., & Guo, Y. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1610008 · Cited by 2
“Human cardiomyopathy is often accompanied by a chronic fi brotic microenvironment, representing end-stage heart failure (Frangogiannis, 2021; Cojan-Minzat et al., 2021; Schlittler et al., 2023; Chang et al., 2023).”
Li, Y., Nice, J. B., Kozinova, M., Adachi, S. Y., Marbán, L., Elliott, K., & Sun, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112652 · Cited by 2
“Moreover, the MI model does not replicate the progressive fibrosis characteristic of DMD-associated pathology [34,35].”
Murray, C., Temperley, H. C., Doyle, R. S., Khair, A. M., Devitt, P., John, A., & Matiullah, S. (2025) · Hearts · doi:10.3390/hearts6040027 · Cited by 2
Angiotensin II induces sex-specific ventricular remodeling in aging C57Bl/6 mice
Khuong, N. B., Mishra, M., Banga, S., & Howlett, S. E. (2025) · GeroScience · doi:10.1007/s11357-025-01924-y · Cited by 5
“In terms of impact on the aging male heart, the AII-induced increase in collagen 1 would be expected to increase ventricular fibrosis and promote systolic dysfunction [48, 50, 51] as we observed in this study.”
Telle, Å., Maleckar, M. M., Wall, S., Powers, J. D., Augustin, C. M., Sundnes, J., & Boyle, P. M. (2025) · Journal of Biomechanical Engineering · doi:10.1115/1.4070346 · Cited by 2
Schubart, J. M., Schaefer, M. K. H., Bonaterra, G. A., Mey, L., Schwarzbach, H., Pankuweit, S., Ausbuettel, F., Eiden, L. E., Weyand, S., Weihe, E., et al. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70118 · Cited by 2
“3 As a result, myocardial stiffness increases and ventricular compliance decreases, leading to diastolic dysfunction.”
Li, X., Dai, Z., Ren, X., Zhao, H., Chan, L., Wu, R., Xiao, X., Liu, Q., & Su, L. (2025) · Journal of Environmental Sciences · doi:10.1016/j.jes.2025.09.017 · Cited by 2
Liu, C., Liu, W., Wang, Y., Jiang, C., Chen, S., Huang, Q., Xiong, X., Wang, L., Zeng, G., & Huang, Q. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168150 · Cited by 2
Circulating Fibrocytes: Cellular Mediators of Tissue Fibrosis
Guo, X., Lu, J., Du, Y., Xia, Z., & Ji, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020557 · Cited by 3
“…gradients are likely engaged in the heart, supported by experimental evidence linking SDF-1 and CXCR4 activation to fibrocyte recruitment and myocardial fibrosis [76], as well as by patient data suggesting that circulating SDF-1 can promote fibrocyte migratory behavior in atrial fibrillation [78].”
InfluentialWang, W., She, T., Wang, Y., Wang, F., Wang, M., Xu, S., Duan, X., & Yang, L. (2026) · BMC Medical Imaging · doi:10.1186/s12880-025-02052-x · Cited by 2
Bai, H., Wu, G., Qin, X., Yang, Q., Yao, Z., Zhang, W., Wang, J., Dong, W., Wang, L., Zhang, X., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101560 · Cited by 2
Zhou, Q., & Guo, K. (2026) · Clinical Science · doi:10.1042/cs20256032 · Cited by 2
Stable and functional regulatory T cell attenuates fibrotic remodeling in heart failure
Taguchi, T., Kawamura, T., Mikami, N., Torigata, K., Harada, A., Fujimura, L., Ito, E., Takeda, M., Miki, K., Sakaguchi, S., et al. (2026) · Regenerative Therapy · doi:10.1016/j.reth.2026.101079 · Cited by 2
“A pivotal feature underlying HF progression is myocardial remodeling, particularly cardiac fibrosis, characterized by excessive deposition of collagen and other extracellular matrix proteins leading to ventricular stiffness and impaired cardiac contractility [3,4].”
InfluentialAdvances in targeting myocardial fibrosis: integrating mechanisms and therapeutics
Xu, Z., & Zhao, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1769016 · Cited by 2
GPT2-mediated Glutamate to α-Ketoglutaric Acid Conversion in Cardiac Fibroblast Promotes Fibrosis
Chen, Y., Liao, F., Wang, J., Zhao, J., Xu, Y., Chen, Q., Hong, T., Lv, K., Li, Q., Chen, X., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101518 · Cited by 2
Wu, M., Tan, J. Y., Zhou, W., Zhang, Z., Gao, Q., Cai, Y., Liao, G., Cao, Z., Zeng, C.-R., Zhang, Y., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.077756 · Cited by 2
Arrhythmic Burden After Myocarditis: From Molecular Mechanisms to Therapeutic Strategies
Curcio, A., Romano, L. R., Rocca, C., Lopes, G. T. A., & Quarta, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.52 · Cited by 3
“31 Cardiac fibroblasts (CFs) play a crucial role in the progression of chronic myocarditis to DCM.”
Inhibition of HO-1 alleviates cardiac fibrosis by improving ferroptosis-mediated aberrant autophagy
Kong, C., Liu, H., Jiang, S., He, Y., Hu, R., Wang, H., Gong, J., Zhu, L., Yu, T., Pang, P., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.286 · Cited by 2
Zhu, J., Sun, D., Zeng, G., Wu, K., Yang, X., Zhu, X., Aierken, D., Ding, S., Wang, X., Ge, J., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02721-5 · Cited by 2
Selective titin cleavage disrupts cardiac mechanical homeostasis to drive heart failure and fibrosis
Freundt, J. K., Hartmann, P., Loescher, C. M., Unger, A., Koser, F., Klotz, A. J., Wildschütz, L., Wachsmuth, L., Hille, S. S., Door, M. M., et al. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00829-z · Cited by 3
“This redistribution may disrupt coordinated force sensing and mechanoresponsive signaling, thereby promoting myofibroblast differentiation 23,25 .”
Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis
Boichenko, V., Frolova, S., Voellenkle, C., Zaccagnini, G., Ferrero, P., Bassareo, P. P., Luciani, G. B., Gorelik, J., & Martelli, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119607 · Cited by 2
“This activation is driven by a complex network of pro-fibrotic and inflammatory signalling, including TGF-β and interleukin-11 (IL-11), which position CFs as key contributors to pathological remodelling and the primary therapeutic targets in CVD [2, 9,10].”
InfluentialZhang, S., Chen, J., Yang, L., Wu, L., Xi, G., Li, X., Chen, A., Wang, X., Niu, Q., Jin, L., et al. (2026) · Echocardiography · doi:10.1111/echo.70547 · Cited by 2
Binek, A., & Angel, P. M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327684 · Cited by 2
Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy
Zhang, H., Shivnaraine, R. V., Ren, L., Thai, P. N., Janicot, R., Zhu, W., Huang, R., Siepe, D. H., Tu, C., Liu, W., et al. (2026) · Science · doi:10.1126/science.aej5896 · Cited by 2
Inflammaging: Role in pathogenesis and molecular diagnostics of age-related dilated cardiomyopathy
Кветной, И. М., Линькова, Н. С., Pukhalskaya, A. E., Козлов, К. Л., Игоревич, Г. Г., & Пальцев, М. А. (2021) · Nauchno-prakticheskii zhurnal «Patogenez» · doi:10.25557/2310-0435.2021.02.67-72 · Cited by 2
Chen, L., Li, M., Shen, M., Zhu, Y., Chen, K., Huang, X., Zheng, C., Wang, Q., Lin, H., Liao, W., et al. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023071 · Cited by 2
Ye, H., Wang, K., Ma, J., Cui, S., Guo, J., Yang, K., & Lyu, L. (2024) · Shock · doi:10.1097/shk.0000000000002344 · Cited by 2
Akimov, O. Y., Mykytenko, A. О., & Kostenko, V. О. (2024) · Medicni perspektivi · doi:10.26641/2307-0404.2024.1.300443 · Cited by 2
Zeyu, Z., Zhuangzhuang, J., Yuwei, S., Xuan, Z., Wang, C., Shuai, W., Peipei, Z., Qiuan, R., Xianliang, W., & Jingyuan, M. (2024) · PubMed Central · doi:10.19852/j.cnki.jtcm.20240402.004 · Cited by 2
Feng, L., Zhu, X., Ji, X., Zhu, H., Ran, T., & Yang, H. (2024) · Pediatric Discovery · doi:10.1002/pdi3.92 · Cited by 2
“21 In this study, the degree of myocardial fibrosis, quantified by calculating CVF, showed left ventricular myocardial fibrosis at 4 weeks after modeling, primarily manifested as interstitial fibrosis.”
Fibrosis uncovered: ADAMTS12 cuts to the core of extracellular matrix drama
Dumoulin, B., & Suszták, K. (2024) · Journal of Clinical Investigation · doi:10.1172/jci183115 · Cited by 2
Rubaiy, H. N. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001643 · Cited by 2
Zhang, Z., Ma, C., Gao, X., Wang, C., Li, Y., Yang, C., Ma, E., & Cheng, M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108033 · Cited by 2
The role of exercise in bolstering cardiac resilience during aging
Saini, A. S., Foote, K., Bennett, M. R., & Vujić, A. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.18 · Cited by 2
The role of SGLT2 inhibitors in protecting cardiovascular health: beyond glycaemic control
Alharbi, S. A., Alsubaiei, A. A., Alkhalifah, A. H., Alshehri, A. A., Alhaggas, S. S., Alhuthli, S. M., Alfaqih, Y. H., Alnajjar, W. Z., Alshaban, G. A., Ahmed, M. S., et al. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20250050 · Cited by 2
“46,47 It was stated that SGLT2 inhibitors are associated with an inhibition or attenuation in cardiac fibrosis and cardiomyocyte hypertrophy.”
NADPH Oxidases in Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Therapeutic Approaches
Adhab, A. H., Altalbawy, F. M. A., Mahdi, M. S., Baldaniya, L., Omar, T. M., Ganesan, S., Juneja, B., Pathak, P. K., Mansoor, A. S., Radi, U. K., et al. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-09976-4 · Cited by 3
“Moreover, the fibrotic tissue can disrupt the normal electrical conduction in the heart, potentially leading to arrhythmias [156].”
PGRMC2 is a pressure-volume regulator critical for myocardial responses to stress in mice
Amirrad, F., La, V., Ohadi, S., Albotaif, M., Webster, S., Pru, J. K., Shamloo, K., Mohieldin, A. M., & Nauli, S. M. (2025) · Nature Communications · doi:10.1038/s41467-025-57707-8 · Cited by 3
Bakhos, J. J., Saliba, Y., Hajal, J., Achkouty, G., Oskaridjian, H., Albuquerque, M., Azevedo, C., Semaan, A., Suffee, N., Balse, E., et al. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf031 · Cited by 2
Song, J., Chen, P., Pan, X., Chen, B., Zang, J., & Zhang, J. (2025) · Echocardiography · doi:10.1111/echo.70144 · Cited by 2
Darouei, B., Amani‐Beni, R., Rad, M. R., Dabaghi, G. G., Eshraghi, R., Bahrami, A., Amini‐Salehi, E., Hashemi, S. M., Mazaheri‐Tehrani, S., & Movahed, M. R. (2025) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.31555 · Cited by 2
Jiang, Z., Wang, L., Li, M., Zhang, Y., & Chen, M. (2025) · Echocardiography · doi:10.1111/echo.70203 · Cited by 2
A computational model of age‐dependent cardiomyocyte apoptosis
Kutumova, E. O., Kiselev, I. N., & Kolpakov, F. (2025) · The Journal of Physiology · doi:10.1113/jp288853 · Cited by 2
Vinarský, V., Pagliari, S., Aldabash, B., Martino, F., Mazzotti, C., Jirakova, K., Garlíková, Z., Iuri, E. D., Kytýř, D., Benzoni, P., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02793-2 · Cited by 3
Tong, R., Wu, T., & Chen, J. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230501151924 · Cited by 2
Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice
Künzel, S. R., Winter, L., Hoffmann, M., Kant, T. A., Thiel, J., Kronstein‐Wiedemann, R., Klapproth, E., Lorenz, K., El‐Armouche, A., & Kämmerer, S. (2023) · Physiological Reports · doi:10.14814/phy2.15809 · Cited by 2
“…fibrotic remodeling (Künzel et al., 2021; Watson et al., 2014) leading to increased myocardial stiffness and diastolic dysfunction (Baum & Duffy, 2011; Burlew & Weber, 2002; Frangogiannis, 2021), thus limiting the long-term prognosis of MI survivors (Frango-giannis, 2017; Talman & Ruskoaho, 2016).”
BackgroundАлександровна, Л. Е., N.N., D., S.B., N., & Александровна, Ш. И. (2023) · Avicenna Bulletin · doi:10.25005/2074-0581-2023-25-4-520-526 · Cited by 2
Endothelial TET2 Regulates Cardiac Remodeling by Modifying Endothelial-to-Mesenchymal TransitionPreprint
Kou, W., Shi, Y., Li, B., Zeng, Y., Zhai, M., You, S., Yu, Q., Gong, S., Zhuang, J., Zhao, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.15.496224 · Cited by 2
O’Donnell, A., & Yutzey, K. E. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.08.006 · Cited by 2
Qian, J., Jackson‐Weaver, O., Shen, Y., Jin, J. J., Chen, Y., Li, M., Subramanyan, R. K., & Xu, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595777 · Cited by 2
Shear wave elastography in cardiac imaging: promise and questions ahead
Edvardsen, T., & Selmer, L. M. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf208 · Cited by 2
Johnson, G., Hart, A., Sujansky, M., Graber, J. H., & Godwin, J. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.705144 · Cited by 2
Non-Ischemic Myocardial Fibrosis in End-Stage Kidney Disease Patients: A New Perspective
Nakata, K., & Joki, N. (2023) · Kidney and Dialysis · doi:10.3390/kidneydial3030027 · Cited by 1
Shankar, T. S., Johnson, E., Hamouche, R., Visker, J. R., Ling, J., Amrute, J., padilla, L., Srinivasan, H., Calder, D., Polishchuk, G., et al. (2026) · Nature Communications · doi:10.21203/rs.3.rs-3390276/v1 · Cited by 1
Supramolecular Peptide‐based Nanomaterials for the Treatment of Fibrosis
Liu, J., & Zou, Q. (2024) · Wiley eBooks · doi:10.1002/9783527841264.ch20 · Cited by 1
The impact of lipoprotein(a) level on cardiac pathologies in diabetes: a cardiac CT study
Yuan, J., Ding, X., Yang, W., Lan, Z., Yu, Y., Yu, L., Dai, X., Wang, Y., & Zhang, J. (2024) · European Radiology · doi:10.1007/s00330-024-10903-4 · Cited by 1
Mazarura, G. R., & Hébert, T. E. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000958 · Cited by 2
Laboratory biomarkers for the prognosis of chronic heart failure
Roytman, A. P., Кузнецова, Т. Е., Belyaev, I., Бугров, А. В., Tazina, S. Y., Dolgov, V. V., & Godkov, M. A. (2024) · Laboratory Service · doi:10.17116/labs2024130315 · Cited by 1
Сергеевна, С. А., & Shcherbakova, S. A. (2024) · The Clinician · doi:10.17650/1818-8338-2024-18-3-k709 · Cited by 1
Jiménez‐González, S., Delgado‐Valero, B., Romero‐Miranda, A., Islas, F., Luaces, M., Ramchandani, B., Cuesta‐Corral, M., Montoro‐Garrido, A., Nieto, M. L., Martínez‐Martínez, E., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100750 · Cited by 1
Zhu, M., Liu, W., Su, S., Gong, M., Liao, G., Fu, F., Chen, G., Rao, Z., Cheng, J., Liu, J., et al. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116699 · Cited by 1
Inhibition of Bif-1 confers cardio-protection in myocardial infarction
Xu, Y., Zheng, Z., Jiang, X. M., Wang, X.-Q.-Y., Xu, Q., Lu, X., Huang, Y., Qin, Y. H., Hou, N., & Liu, Y. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00473.2024 · Cited by 1
Prognostic thresholds of diffuse myocardial fibrosis on cardiovascular magnetic resonance
Yeo, T. M., Le, T., Bryant, J., Lee, V., Boubertakh, R., Foo, R., Wang, W., & Chin, C. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf113 · Cited by 1
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.